Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Shanghai Haohai Biological Technology Co., Ltd. Class H ( (HK:6826) ).
Shanghai Haohai Biological Technology Co., Ltd. has announced its annual results for the year ended 31 December 2024, declaring a final ordinary cash dividend of RMB 0.6 per share. This announcement reflects the company’s financial performance and commitment to returning value to its shareholders, although specific details regarding the payment date and exchange rate are yet to be disclosed.
More about Shanghai Haohai Biological Technology Co., Ltd. Class H
Shanghai Haohai Biological Technology Co., Ltd. operates in the biotechnology industry, focusing on the development and production of biological materials and medical devices. The company is known for its innovative solutions in the healthcare sector, catering to a diverse market with a range of products.
YTD Price Performance: 8.44%
Average Trading Volume: 465,565
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$13.97B
See more data about 6826 stock on TipRanks’ Stock Analysis page.